Compare Novo Nordisk A/S (NVO) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Toronto-Dominion Bank — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Toronto-Dominion Bank trades at $120.5 (market cap $197.03B). The key difference: Novo Nordisk A/S and Toronto-Dominion Bank are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | TD | |
|---|---|---|
Market Cap | $220.53B | $197.03B |
Sector | Health | Financials |
52-Week High | $71.70 | $124.80 |
52-Week Low | $35.29 | $72.55 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | 2.62% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
